By Fineline Cube OmniAb, Inc. (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly (NYSE: LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expertise in ion channel discovery and screening.
Deal Milestone
| Item | Detail |
|---|---|
| Parties | OmniAb, Inc. (NASDAQ: OABI) and Eli Lilly |
| Agreement Type | Global collaboration and license agreement |
| Program | New ion channel program (target and modality undisclosed) |
| Upfront Payment | Yes (amount undisclosed) |
| Milestone Payments | Up to $370 million (research, development and commercial) |
| Royalties | Tiered royalties on global net sales |
| Announcement Date | 17 Aug 2026 |
Program & Technology Profile
- Focus Area: Ion channels — a historically difficult class of therapeutic targets associated with complex discovery and screening challenges.
- OmniAb Contribution: The company’s technology platform and specialized expertise in ion channel discovery and screening.
- Target & Modality: Undisclosed under the terms of the agreement.
- Deal Structure: Upfront payment, up to $370 million in research, development and commercial milestone payments, and tiered royalties on global net sales.
Market Impact & Outlook
- Validation of Platform: A collaboration with Eli Lilly, one of the world’s largest pharmaceutical companies, represents a significant external validation of OmniAb’s discovery technology, particularly in the technically demanding ion channel space.
- Revenue Visibility: The upfront payment, milestone structure and royalty stream create potential multi‑stage revenue visibility for OmniAb (NASDAQ: OABI) as the program advances.
- Strategic Positioning: For Eli Lilly, the deal adds an early‑stage ion channel asset sourced through specialist platform expertise, reinforcing its strategy of augmenting internal discovery with external innovation.
- Sector Signal: The agreement underscores continued big‑pharma demand for antibody and therapeutic discovery platforms capable of addressing hard‑to‑target classes.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding collaboration milestones, program development and potential royalty revenue. Actual results may differ due to risks including research outcomes, development timelines and competitive dynamics.-Fineline Info & Tech